

PRESS RELEASE - STOCKHOLM, AUGUST 28, 2009

Conversion of shares

According to RaySearch's articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company.

In August, at the request of shareholders, 252,756 Class A shares were converted to Class B shares. The total number of votes in the company thereafter amounts to 145,756,485.

The total number of registered shares in the company amounts to 34,282,773, of which 12,385,968 are Class A shares and 21,896,805 are Class B shares.

ABOUT RAYSEARCH

RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch's products are mainly sold through license agreements with leading partners such as Philips, Varian, Siemens, Nucletron, IBA Dosimetry and TomoTherapy. Thirteen products have been launched to date and RaySearch's software is used at some 1,500 clinics in more than 30 countries. In addition, existing license agreements cover more than 15 other products that are scheduled to be launched in the coming years. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on the NASDAQ OMX Nordic Exchange Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com.

FOR FURTHER INFORMATION, CONTACT:

Anders Martin-Löf, CFO, RaySearch Laboratories AB (publ)

Telephone: +46 (0)8-545 061 30

anders.martin-lof@raysearchlabs.com